UR9A.F CLINUVEL PHARMAC.ADRS1

Healthcare Biotechnology Frankfurt Exchange
4.40 EUR
Close of Nov 12, 2026
4.10 7.20
Market cap
EUR 222M
P/E
11.3x
P/B
1.31x
ROE
12.4%
Dividend yield
0.72%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is UR9A.F undervalued?

Graham number
Price4.40
Graham value5.43
Discount18.9%

UR9A.F trades 18.9% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CLINUVEL PHARMAC.ADRS1 fundamental analysis

No fundamental analysis for CLINUVEL PHARMAC.ADRS1 yet.

CLINUVEL PHARMAC.ADRS1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CLINUVEL PHARMAC.ADRS1

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimu…

Full company profile